News headlines about Hologic (NASDAQ:HOLX) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Hologic earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 45.0186209642258 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s rankings:
- Computer Aided Detection System Market Study including key players: Hologic, EDDA Technology, Siemens … (factsweek.com)
- Hologic (HOLX) vs. Essilor International (ESLOY) Critical Contrast (americanbankingnews.com)
- Evercore ISI Initiates Coverage on Hologic (HOLX) (americanbankingnews.com)
- Hologic (HOLX) Upgraded by Bank of America to “Buy” (americanbankingnews.com)
- Technical Indicators in Focus – Hologic Inc (NASDAQ: HOLX) (stockspen.com)
Shares of NASDAQ:HOLX traded down $0.03 during mid-day trading on Friday, reaching $37.36. The company had a trading volume of 3,060,376 shares, compared to its average volume of 2,252,516. The company has a current ratio of 1.25, a quick ratio of 0.98 and a debt-to-equity ratio of 0.87. The stock has a market capitalization of $10,331.12, a PE ratio of 18.40, a price-to-earnings-growth ratio of 1.68 and a beta of 0.84. Hologic has a one year low of $35.33 and a one year high of $46.80.
Several equities analysts have commented on HOLX shares. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a research report on Thursday, January 4th. Goldman Sachs cut shares of Hologic from a “conviction-buy” rating to a “buy” rating and set a $43.00 target price on the stock. in a research report on Monday, March 26th. Zacks Investment Research cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Tuesday, March 6th. Deutsche Bank cut shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research report on Friday, January 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $48.00 target price (up previously from $46.00) on shares of Hologic in a research report on Tuesday, December 5th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the company’s stock. Hologic currently has a consensus rating of “Buy” and an average target price of $47.21.
In related news, Director Namal Nawana purchased 6,600 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were bought at an average price of $37.88 per share, with a total value of $250,008.00. Following the acquisition, the director now owns 6,954 shares of the company’s stock, valued at approximately $263,417.52. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Allison P. Bebo sold 7,000 shares of Hologic stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $38.75, for a total transaction of $271,250.00. The disclosure for this sale can be found here. Insiders own 0.79% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2018/04/01/hologic-holx-earns-daily-coverage-optimism-rating-of-0-20.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.